Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 0069-4031

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 0069-4031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Doxorubicin 01)

Chemical structure of doxorubicin hydrochloride, showing the molecular formula C27H29NO11•HCl and molecular weight 579.99.*

FDA Label Image

Figure 1 (Doxorubicin 02)

A hazard ratio forest plot comparing outcomes of six studies labeled by trial names, evaluating doxorubicin-based treatments against CMF. The horizontal axis shows hazard ratios with a boundary for non-inferiority at 1.06, with markers representing hazard ratios and confidence intervals for each study. A diamond shape represents a combined estimate of doxorubicin-based studies, positioned near or below the line of equivalence.*

FDA Label Image

Figure 2 (Doxorubicin 03)

A forest plot chart showing hazard ratios with 95% confidence intervals across multiple clinical trials comparing Doxorubicin Hydrochloride to CMF. The trials listed include NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. The horizontal axis ranges from 0 to 2, indicating whether Doxorubicin is better or worse than CMF.*

FDA Label Image

Logo (Doxorubicin 04)

FDA Label Image

Logo (Doxorubicin 04a)

FDA Label Image

Principal Display Panel (10 mg/5 mL ONCO-TAIN® Label)

Label for Doxorubicin Hydrochloride Injection 2 mg/mL (10 mg/5 mL), a single-dose vial for intravenous use only. The label includes storage instructions to refrigerate between 2°C and 8°C, warning that it is a hazardous drug, and advises discarding unused portions. Distributed by Pfizer Labs, Division of Pfizer Inc.*

FDA Label Image

Principal Display Panel (10 mg/5 mL ONCO-TAIN® Carton)

Packaging label for Doxorubicin Hydrochloride Injection 10 mg/5 mL (2 mg/mL) single-dose vial by Pfizer Laboratories Division of Pfizer Inc. The label notes intravenous use only and includes storage instructions to refrigerate between 2°C and 8°C. The label also features warnings of hazardous drug and the Novaplus branding.*

FDA Label Image

Principal Display Panel (20 mg/10 mL ONCO-TAIN® Label)

Label for Doxorubicin Hydrochloride Injection 2 mg/mL (20 mg/10 mL) single-dose vial by Pfizer Laboratories Div Pfizer Inc. The label states it is for intravenous use only, warns it is a hazardous drug, and includes storage instructions to keep refrigerated between 2°C and 8°C. It also features NDC 0069-4031-12 and a lot and expiration date area.*

FDA Label Image

Principal Display Panel (20 mg/10 mL ONCO-TAIN® Carton)

Label for Doxorubicin Hydrochloride Injection 20 mg/10 mL (2 mg/mL) single-dose vial by Pfizer Laboratories Div Pfizer Inc. The label states it is an intravenous use only, hazardous drug, sterile isotonic solution stored refrigerated between 2°C and 8°C, protected from light. The label includes the NovaPlus logo and barcode with distribution details for Pfizer Labs, Division of Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.